Regencell Bioscience Holdings (RGC) is trading up at $7.24 (+6.16%), as of the latest quote. It operates in the Health Care sector.
| FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$391.0K | −$812.4K | −$1.38M | −$7.62M | −$6.27M | −$4.74M | −$3.77M |
| Net income | −$391.0K | −$812.4K | −$1.35M | −$7.45M | −$5.87M | −$4.30M | −$3.58M |
| EPS (diluted) | — | −$0.08 | −$0.13 | −$0.58 | −$1.19 | −$0.87 | −$0.72 |
| Balance sheet | |||||||
| Cash and equivalents | $243.3K | $387.0K | $59.4K | $6.42M | $1.56M | $2.96M | $2.42M |
| Total assets | — | $514.0K | $340.1K | $18.0M | $12.6M | $8.44M | $5.76M |
| Total liabilities | — | $3.16M | $4.34M | $938.0K | $632.3K | $219.5K | $895.3K |
| Shareholders' equity | −$1.84M | −$2.65M | −$4.00M | $17.1M | $12.0M | $8.22M | $4.86M |
| Cash flow | |||||||
| Operating cash flow | −$391.0K | −$726.6K | −$767.3K | −$5.27M | −$4.96M | −$4.00M | −$3.11M |
| Capital expenditure | — | $117.8K | — | $780.9K | $27.4K | $5.38K | $152.7K |
| Free cash flow | — | −$844.4K | — | −$6.05M | −$4.99M | −$4.01M | −$3.27M |
From Regencell Bioscience Holdings's 20-F filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Regencell Bioscience Holdings in our feed yet.